- Home
- NAMS
NAMS
NewAmsterdam Pharma Company N.V.
as 05-09-2025 12:40pm EST
| Founded: | 2019 | Country: | Netherlands |
| Employees: | N/A | City: | NARRDEN |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $42.83 | AVG Volume (30 days): | 601.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.85 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.06 - $27.29 | Next Earning Date: | 05-08-2025 |
| Revenue: | $47,140,000 | Revenue Growth: | 586.97% |
| Revenue Growth (this year): | -59.66% | Revenue Growth (next year): | -7.33% |
Latest NewAmsterdam Pharma Company N.V. News
NAMS Breaking Stock News: Dive into NAMS Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
GlobeNewswire
2 days ago
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025
GlobeNewswire
7 days ago
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
9 days ago
NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress
GlobeNewswire
22 days ago
NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors
GlobeNewswire
a month ago
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Investor's Business Daily
a month ago
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?
GlobeNewswire
a month ago
NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference
Compare NAMS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NAMS NewAmsterdam Pharma Company N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.